Latest Cancer Research News

Page 2 of 4
Race Oncology has received ethics approval to launch its HARNESS-1 Phase 1a/b trial testing RC220 combined with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward addressing resistance to current therapies.
Ada Torres
Ada Torres
26 Nov 2025
Chimeric Therapeutics has received a $4.5 million R&D tax incentive refund from the Australian Government, underscoring its ongoing investment in innovative cancer cell therapies.
Ada Torres
Ada Torres
24 Nov 2025
Pro Medicus Limited’s U.S. subsidiary, Visage Imaging, has landed three new cloud-based contracts worth a combined minimum of A$29 million, reinforcing its strong foothold across diverse healthcare segments.
Ada Torres
Ada Torres
24 Nov 2025
Noxopharm Limited has been granted its first US patent for the Sofra™ technology platform, marking a key milestone in its cancer immunotherapy research. This patent protects the company’s innovative immune-modulatory oligonucleotides, underpinning its expanding pipeline in a rapidly growing market.
Ada Torres
Ada Torres
22 Oct 2025
Pro Medicus Limited’s European arm, Visage Imaging, has landed a significant five-year, A$10 million contract to supply next-generation imaging technology to University Hospital Heidelberg and the German Cancer Research Institute, marking a strategic expansion in Europe.
Ada Torres
Ada Torres
8 Oct 2025
Arovella Therapeutics has demonstrated that its novel CLDN18.2 CAR-T cells effectively eliminate pancreatic cancer cells in vitro, matching the performance of a leading competitor’s product. The company is now advancing this CAR into its innovative iNKT cell platform to tackle solid tumours.
Ada Torres
Ada Torres
2 Oct 2025
(E,E)-bisantrene, Race Oncology’s lead anticancer candidate, operates by binding to G4-DNA and RNA structures, revealing a novel mechanism that disrupts key cancer drivers including the MYC gene.
Ada Torres
Ada Torres
2 Oct 2025
INOVIQ Limited has demonstrated that its CAR-NK-exosome therapy kills over 90% of triple-negative breast cancer cells within 10 hours in laboratory tests, validating its potential as a next-generation cancer treatment.
Ada Torres
Ada Torres
22 Sept 2025
Cleo Diagnostics has received encouraging feedback from the U.S. FDA on its ovarian cancer pre-surgical triage test, reinforcing its clinical trial design and regulatory strategy ahead of a critical 510(k) submission.
Ada Torres
Ada Torres
15 Sept 2025
Noxopharm’s Sofra™ technology shows promising results in collaboration with US biotech Tezcat Biosciences, advancing targeted drug delivery for cancer and inflammatory diseases.
Ada Torres
Ada Torres
5 Aug 2025
Chimeric Therapeutics has advanced its CHM CDH17 CAR-T program with dose escalation and FDA Fast Track status, alongside promising early results in AML trials and a successful $6.6 million capital raise.
Ada Torres
Ada Torres
29 July 2025
Algorae Pharmaceuticals has advanced its AI-driven drug discovery platform into preclinical validation through a strategic collaboration with the Peter MacCallum Cancer Centre, while progressing its therapeutic pipeline and commercial leadership.
Ada Torres
Ada Torres
29 July 2025